Prosecution Insights
Last updated: August 13, 2026

Merz Pharma GmbH & Co. Kgaa

7 pending office actions • 5 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days

Portfolio Summary

7
Total Pending OAs
5
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
0
Due this month
1
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (2)Due ≤ 60 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (29%)
5
Medium (71%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other1 (14%)
§103 only4 (57%)
Double-patenting + other1 (14%)
Multi-statute (no §101)1 (14%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

5
Life Sciences
71% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
2
Business / Other
29% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

70 h
Manual time on pending OAs
14 h
Time saved (low, 20%)
24 h
Time saved (mid, 35%)
0.6 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
CHHAY, BONIRATH 1 75.0% +0.0%
FAN, LYNN Y 1 47.6% +48.7%
ALDARONDO, DASIA ALI 1 0.0% +0.0%
PURDY, KYLE A 1 41.0% +36.5%
NGUYEN, NGOC-ANH THI 1 30.0% +48.4%
GOUGH, TIFFANY MAUREEN 1 31.4% +46.9%
MATTISON, LORI K 1 14.7% +26.7%

Hard Cases (4)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
17255852 FATTY ACID-GRAFTED HYALURONIC ACID, DERMAL FILLER FORMULATIONS COMPRISING SAME, PROCESS FOR PREPARATION AND USE THEREOF MATTISON, LORI K 2d overdue
18620513 COMPOSITION COMPRISING BOTULINUM TOXIN FAN, LYNN Y 34d
18841985 USE OF BOTULINUM TOXIN FOR REDUCTION OF SKIN PORE SIZE AND SEBUM PRODUCTION CHHAY, BONIRATH
18573732 CROSS-LINKING POLYSACCHARIDE WITH FIBROIN AND USES OF THE OBTAINED MATERIAL ALDARONDO, DASIA ALI

Interview Candidates (5)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
17431997 NOVEL USES OF BOTULINUM NEUROTOXIN FOR THE TREATMENT OF TREMOR GOUGH, TIFFANY MAUREEN 44d overdue
17255852 FATTY ACID-GRAFTED HYALURONIC ACID, DERMAL FILLER FORMULATIONS COMPRISING SAME, PROCESS FOR PREPARATION AND USE THEREOF MATTISON, LORI K 2d overdue
18620513 COMPOSITION COMPRISING BOTULINUM TOXIN FAN, LYNN Y 34d
18178041 COMPOSITION FOR IMPROVING THE APPEARANCE OF AGEING SKIN PURDY, KYLE A
17759420 INJECTABLE COMPOSITION FOR SKIN AND SOFT TISSUE AUGMENTATION NGUYEN, NGOC-ANH THI

Top Art Units

Art UnitApps
1759 1
1611 1
1615 1
1651 1
1619 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18841985 USE OF BOTULINUM TOXIN FOR REDUCTION OF SKIN PORE SIZE AND SEBUM PRODUCTION CHHAY, BONIRATH §103§112 Non-Final OA Pending Aug 27, 2024
18620513 COMPOSITION COMPRISING BOTULINUM TOXIN FAN, LYNN Y 1759 §101§103Other Non-Final OA 34d Pending Mar 28, 2024
18573732 CROSS-LINKING POLYSACCHARIDE WITH FIBROIN AND USES OF THE OBTAINED MATERIAL ALDARONDO, DASIA ALI §103 Non-Final OA Pending Dec 22, 2023
18178041 COMPOSITION FOR IMPROVING THE APPEARANCE OF AGEING SKIN PURDY, KYLE A 1611 §103 Non-Final OA Pending Mar 03, 2023
17759420 INJECTABLE COMPOSITION FOR SKIN AND SOFT TISSUE AUGMENTATION NGUYEN, NGOC-ANH THI 1615 §103 Non-Final OA Pending Jul 25, 2022
17431997 NOVEL USES OF BOTULINUM NEUROTOXIN FOR THE TREATMENT OF TREMOR GOUGH, TIFFANY MAUREEN 1651 §103DP Final Rejection 44d overdue Pending Aug 18, 2021
17255852 FATTY ACID-GRAFTED HYALURONIC ACID, DERMAL FILLER FORMULATIONS COMPRISING SAME, PROCESS FOR PREPARATION AND USE THEREOF MATTISON, LORI K 1619 §103 Final Rejection 2d overdue Pending Dec 23, 2020

Managing Merz Pharma GmbH & Co. Kgaa's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month